USS Investment Management Ltd Purchases 11,950 Shares of Boston Scientific Corporation $BSX

USS Investment Management Ltd lifted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 4.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 269,031 shares of the medical equipment provider’s stock after buying an additional 11,950 shares during the period. USS Investment Management Ltd’s holdings in Boston Scientific were worth $16,876,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of BSX. Brighton Jones LLC boosted its stake in shares of Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after purchasing an additional 226 shares in the last quarter. FWL Investment Management LLC purchased a new position in Boston Scientific in the 2nd quarter worth $26,000. Main Street Financial Solutions LLC lifted its stake in Boston Scientific by 35.3% in the second quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock worth $812,000 after purchasing an additional 1,971 shares during the last quarter. Ieq Capital LLC boosted its position in Boston Scientific by 97.0% during the second quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock valued at $13,275,000 after buying an additional 60,860 shares during the period. Finally, HUB Investment Partners LLC boosted its position in Boston Scientific by 56.2% during the second quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock valued at $763,000 after buying an additional 2,556 shares during the period. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

Shares of Boston Scientific stock opened at $42.98 on Thursday. The business has a 50 day moving average of $51.68 and a 200 day moving average of $69.93. Boston Scientific Corporation has a 52 week low of $42.25 and a 52 week high of $109.50. The company has a market cap of $63.89 billion, a PE ratio of 17.98, a P/E/G ratio of 0.82 and a beta of 0.56. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities research analysts forecast that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Boston Scientific declared that its board has approved a share buyback plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

Insider Transactions at Boston Scientific

In related news, Director Edward J. Ludwig acquired 3,580 shares of the stock in a transaction on Wednesday, May 20th. The stock was acquired at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the acquisition, the director directly owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. This represents a 16.44% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David C. Habiger acquired 2,250 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were purchased at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the transaction, the director owned 13,878 shares in the company, valued at approximately $776,057.76. This represents a 19.35% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders purchased 9,800 shares of company stock valued at $554,012. Company insiders own 0.34% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on BSX. Daiwa Securities Group lowered Boston Scientific from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. BTIG Research restated a “buy” rating and set a $65.00 price target on shares of Boston Scientific in a research report on Tuesday, June 16th. Weiss Ratings cut Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. Oppenheimer set a $90.00 price objective on Boston Scientific in a research report on Thursday, April 23rd. Finally, Raymond James Financial reissued an “outperform” rating and set a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a research note on Monday, March 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $83.36.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific completed its POLARx Post Approval Study, adding fresh clinical data to its atrial fibrillation growth story and supporting the long-term outlook for its electrophysiology business. Boston Scientific’s POLARx Study Completion Adds Fresh Data to Atrial Fibrillation Growth Story
• Positive Sentiment: The company’s latest reported revenue growth remains strong, with Q1 sales up 11.6% year over year, which helps reinforce the durability of Boston Scientific’s core medtech franchise.
• Neutral Sentiment: Boston Scientific invested $1.5 billion for a 34% stake in MiRus and secured an option to buy its TAVR system, a strategic move that could expand its structural heart pipeline over time. Boston Scientific (BSX) Invests $1.5B in MiRus for Equity Stake and TAVR Acquisition Option
• Neutral Sentiment: Stifel lowered its price target to $65 from $75 but kept a Buy rating, while other analysts also trimmed earnings estimates only slightly; the cuts suggest some caution, but not a full deterioration in the long-term thesis. Stifel Cuts PT on Boston Scientific Corporation (BSX)- Here’s Why
• Negative Sentiment: Recent analyst commentary and social-media chatter focused on softer demand for the Watchman device, bundling pressure, and technical weakness near multi-year lows, which likely contributed to the stock’s decline. Boston Scientific Stock (BSX) Opinions on Recent Analyst Downgrades
• Negative Sentiment: Boston Scientific also declined in the latest session despite a broader market gain, reflecting investor concern that recent analyst revisions and product-specific pressures may outweigh the company’s fundamental growth. Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to Note

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.